title: Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.
abstract: This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.
authors.affiliation: Centre d'Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.forename: Sarah
authors.initials: S
authors.lastname: Sanglier-Cianférani
authors.forename: Alain
authors.initials: A
authors.lastname: Van Dorsselaer
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000032:analysis*; D000911:Antibodies, Monoclonal / Q000032:analysis; D061067:Antibodies, Monoclonal, Humanized / Q000032:analysis; D059451:Biosimilar Pharmaceuticals / Q000032:analysis*; D000068818:Cetuximab; D006801:Humans; D018796:Immunoconjugates / Q000032:analysis*; D007140:Immunoglobulin Fab Fragments / Q000032:analysis*; D007074:Immunoglobulin G / Q000032:analysis*; D051379:Mice; D015202:Protein Engineering; D021241:Spectrometry, Mass, Electrospray Ionization; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D017550:Spectroscopy, Fourier Transform Infrared; D000068878:Trastuzumab
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D059451:Biosimilar Pharmaceuticals; D018796:Immunoconjugates; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D000068878:Trastuzumab; D000068818:Cetuximab